Holocene Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Holocene Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.87M	Sell	250,000 -350,000	-58%	-$6.34M	0.01%	419
2026 Q1	$11.2M	Buy	+600,000	New	+$9.94M	0.03%	314
2025 Q2	–	Sell	-188,989	Closed	-$7.38M	–	831
2025 Q1	$7.38M	Sell	188,989 -1,396,178	-88%	-$60.2M	0.02%	314
2024 Q4	$85.8M	Hold	1,585,167	–	–	0.27%	107
2024 Q3	$79.9M	Sell	1,585,167 -41,174	-3%	-$1.93M	0.32%	102
2024 Q2	$71.5M	Buy	1,626,341 +171,472	+12%	+$7.26M	0.3%	101
2024 Q1	$73.1M	Buy	1,454,869 +493,539	+51%	+$26.8M	0.27%	120
2023 Q4	$58.1M	Buy	961,330 +855,508	+808%	+$44.1M	0.23%	137
2023 Q3	$6.03M	Buy	+105,822	New	+$5.84M	0.03%	360

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Holocene Advisors's MLTX Position: Q2 2026 in Review

Holocene Advisors reduced its MoonLake Immunotherapeutics (MLTX) stake by 58% in Q2 2026, selling an estimated $6.34M and leaving 250,000 shares worth $4.87M. The position accounts for 0.01% of the portfolio, ranked #419.

Holocene Advisors first reported a position in MLTX in Q3 2023 and has held it in 9 quarters since. The position peaked at $85.8M in Q4 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Holocene Advisors held 250,000 shares of MoonLake Immunotherapeutics worth $4.87M as of Q2 2026.
Holocene Advisors sold 350,000 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $6.34M.
MoonLake Immunotherapeutics made up 0.01% of Holocene Advisors's portfolio in Q2 2026, its #419 holding.
Holocene Advisors first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 9 quarters since.
Holocene Advisors's MoonLake Immunotherapeutics position peaked at $85.8M in Q4 2024.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.